Pharmacologic class (EPC) · 8 drug pages

Muscle relaxant: adverse event reports filed with FDA

20,135 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

20,135
reports across the class: 0.1% of all reports; 994
reports, 12 months to June 2026: 1,257 in the 12 months before; 86.6%
marked serious by the reporter: 57.4% across all reports; 8
drugs with a page: brand and generic names counted separately

Muscle relaxant is a pharmacologic class (an FDA Established Pharmacologic Class) with 8 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 20,135 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026.

994 reports arrived in the 12 months to June 2026, down 21% from 1,257 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 86.6% of the class's reports are marked serious, 51.2% record death among the outcomes and 26.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are completed suicide (21.8%), toxicity to various agents (18%) and pain (10.7%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Cyclobenzaprine	generic	8,750	560	90.5%	Toxicity to various agents
Carisoprodol	generic	4,095	28	92.1%	Completed suicide
Methocarbamol	generic	2,111	245	79.6%	Completed suicide
Cyclobenzaprine hydrochloride	generic	1,591	115	86.3%	Pain
SomaCarisoprodol	brand	1,316	5	76.3%	Drug dependence
Metaxalone	generic	925	12	73.7%	Completed suicide
Cyclobenzaprine hcl	generic	763	0	88.1%	Completed suicide
RobaxinMethocarbamol	brand	584	29	57.5%	Drug hypersensitivity

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Completed suicidedeath by suicide21.8%4,390
Toxicity to various agentspoisoning or toxic effect of one or more substances18%3,619
Painpain, site not specified10.7%2,149
Drug abusemisuse of a medicine9.5%1,914
Drug ineffectivethe medicine did not work as expected8.1%1,631
Overdosea dose above the recommended amount7.9%1,587
Constipationconstipation7%1,405
Drug hypersensitivityan allergic-type reaction to a medicine6.9%1,396
Cardiac arrestthe heart stopped6.5%1,315
Off label useused for a purpose or in a way not on the label6.4%1,289
Respiratory arrestbreathing stopped6%1,214
Hypotensionlow blood pressure5.8%1,158
Falla fall5.6%1,125
Headachehead pain5.4%1,084
Cardio-respiratory arrestthe heart and breathing stopped5.2%1,046
Depressed level of consciousness5.2%1,044
Deaththe patient died; cause not stated by this term5.2%1,037
Hypertensionhigh blood pressure4.8%969
Hepatic enzyme increasedraised liver enzymes4.7%952
Cognitive disorderproblems with thinking or memory4.5%907
Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease4.4%889
Mobility decreasedreduced ability to move about4.4%887
Sedationdrowsiness from a medicine4.2%853
Hypersensitivityan allergic-type reaction4.2%851
Balance disorderproblems with balance4.2%843

Solid bar: share of all class reports. Hollow bar: the median share across the 8 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death51.2%10,314

Life-threatening6%1,211

Hospitalisation (initial or prolonged)26.5%5,327

Disability3.2%650

Congenital anomaly2.1%415

Other serious42.2%8,500

Not serious13.4%2,698

Patient age

Under 20.5%91

2 to 110.5%109

12 to 171.4%290

18 to 4428.6%5,759

45 to 6432.4%6,526

65 to 745.4%1,088

75 and over7%1,406

Age not given24.2%4,866

Who reported

Physician34.1%6,860

Pharmacist9.8%1,965

Other health professional31.7%6,374

Lawyer1.2%248

Consumer or non-health professional18.6%3,755

Not given4.6%933

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Muscle relaxant reports

Which drugs are in the Muscle relaxant class on this site?

Cyclobenzaprine, Carisoprodol, Methocarbamol, Cyclobenzaprine hydrochloride, Soma and Metaxalone and 2 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

20,135 reports through June 2026, 994 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

completed suicide (21.8%), toxicity to various agents (18%), pain (10.7%), drug abuse (9.5%) and drug ineffective (8.1%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.